Literature DB >> 1361871

Identification of alpha 1-adrenoceptor subtypes in the rat vas deferens: binding and functional studies.

T Ohmura1, M Oshita, S Kigoshi, I Muramatsu.   

Abstract

1. The alpha 1-adrenoceptor subtypes of the prostatic and epididymal portion of rat vas deferens were characterized in binding and functional experiments. 2. In saturation experiments, [3H]-prazosin bound to two distinct affinity sites in the epididymal portion of rat vas deferens (pKD = 10.1 +/- 0.13 and 9.01 +/- 0.15, Bmax = 507 and 1231 fmol mg-1 protein, respectively). In the prostatic portion [3H]-prazosin bound to a single affinity site (pKD = 9.82 +/- 0.04, Bmax = 924 fmol mg-1 protein). 3. In the displacement experiments, unlabelled prazosin displaced biphasically the binding of 200 pM [3H]-prazosin to the epididymal portion; the resulting two pKI values were consistent with the affinity constants obtained in the saturation experiments. WB4101 (2-(2,6-dimethoxy-phenoxyethyl)-amino-methyl-1,4-benzodioxane) and benoxathian also discriminated the two affinity sites in the epididymal portion and the population of low affinity sites for the three antagonists was approximately 40%. On the other hand, the prostatic portion predominantly showed a single affinity site for prazosin, WB4101 and benoxathian, although the presence of a small proportion (less than 10%) of the low affinity site could be detected. HV723 (alpha-ethyl-3,4,5-trimethoxy-alpha-(3-((2-(2-methoxyphenoxy)ethyl)-a min o)- propyl) benzeneacetonitrile fumarate) displaced the [3H]-prazosin binding monophasically with a low affinity in both halves. 4. Pretreatment with chlorethylclonidine (CEC) at concentrations higher than 1 microM inhibited 700 pM [3H]-prazosin binding to the prostatic portion by approximately 50%. However, the inhibition in the epididymal portion was much less (approximately 21% at 50 microM CEC).5. In the functional study, the contractile response to noradrenaline was competitively inhibited by prazosin, WB4101, benoxathian and HV723 with similar and low affinities (pKB value ranging from 8.0to 9.0) in the epididymal portion of rat vas deferens. In the prostatic portion of rat vas deferens,noradrenaline also produced a contraction, but the maximal amplitude of contraction developed was approximately one-fourth of that in the epididymal portion. Prazosin and WB4101 also inhibited the contractile response of the prostatic portion with the pKB values similar to those obtained in the epididymal portion. The contractions to noradrenaline in both portions were potently attenuated by 1 LM nifedipine but were not affected by pretreatment with 1O LM CEC.6. Under conditions where P2x-purinoceptors and prejunctional M2-adrenoceptors were blocked, electrical transmural stimulation produced a rapidly developing phasic contraction and a subsequent tonic contraction in the epididymal portion of rat vas deferens. The phasic and tonic contractions were inhibited in a concentration-dependent manner by prazosin (ICs = 25.7 and 25.9 nm, respectively),WB4101 (ICo= 7.27 and 7.58 nM), benoxathian (ICs = 10.9 and 8.66 nM) and HV723 (ICs = 15.9 and 14.9 nM). Nifedipine selectively attenuated the tonic contraction induced by electrical stimulation, and the residual phasic response was inhibited by the antagonists mentioned above with similar affinities to those in the absence of nifedipine. CEC (10 gM) had little effect on the adrenergic neurogenic contractions.7. The present results indicate the presence of two distinct alpha&-adrenoceptor subtypes in the rat vas deferens, which show respectively high and low affinities for each of prazosin, WB4101 and benoxathian,and presumably correspond to putative MIA and alL subtypes according to the recent am-adrenoceptorsubclassifications. The contractions induced by exogenous and endogenous noradrenaline seem to be predominantly mediated through the alL subtype. The heterogeneous distribution of the low affinity sites(alL subtype) may well explain differences in functional responsiveness between the two portions of rat vas deferens.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1361871      PMCID: PMC1907766          DOI: 10.1111/j.1476-5381.1992.tb14509.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  34 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

Review 2.  Catecholamine action on smooth muscle.

Authors:  E Bülbring; T Tomita
Journal:  Pharmacol Rev       Date:  1987-03       Impact factor: 25.468

3.  Effects of St-587 on the alpha-adrenoceptors in the bisected rat vas deferens.

Authors:  A Badia; J Sallés
Journal:  J Pharm Pharmacol       Date:  1989-09       Impact factor: 3.765

Review 4.  Quantitative analysis of drug-receptor interactions: II. Determination of the properties of receptor subtypes.

Authors:  P B Molinoff; B B Wolfe; G A Weiland
Journal:  Life Sci       Date:  1981-08-03       Impact factor: 5.037

5.  Pharmacological studies on the selectivity of HV-723, a new alpha-1 adrenoceptor antagonist.

Authors:  M Oshita; Y Iwanaga; S Hashimoto; K Morikawa; I Muramatsu
Journal:  Jpn J Pharmacol       Date:  1988-07

Review 6.  Alpha-adrenoceptor subclassification by classical and response-related methods: same question, different answers.

Authors:  J McGrath; V Wilson
Journal:  Trends Pharmacol Sci       Date:  1988-05       Impact factor: 14.819

7.  Ligand: a versatile computerized approach for characterization of ligand-binding systems.

Authors:  P J Munson; D Rodbard
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

8.  Characterization of alpha 1-adrenergic receptor subtypes in rat brain: a reevaluation of [3H]WB4104 and [3H]prazosin binding.

Authors:  A L Morrow; I Creese
Journal:  Mol Pharmacol       Date:  1986-04       Impact factor: 4.436

9.  Selective alpha-2 blocking action of DG-5128 in the dog mesenteric artery and rat vas deferens.

Authors:  I Muramatsu; M Oshita; K Yamanaka
Journal:  J Pharmacol Exp Ther       Date:  1983-10       Impact factor: 4.030

10.  Heterogeneity of alpha 1-adrenergic receptors revealed by chlorethylclonidine.

Authors:  C Han; P W Abel; K P Minneman
Journal:  Mol Pharmacol       Date:  1987-10       Impact factor: 4.436

View more
  26 in total

1.  Pharmacological analysis of the novel, selective alpha1-adrenoceptor antagonist, KMD-3213, and its suitability as a tritiated radioligand.

Authors:  S Murata; T Taniguchi; I Muramatsu
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

2.  Investigation of the subtypes of alpha1-adrenoceptor mediating contractions of rat vas deferens.

Authors:  V Honner; J R Docherty
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

3.  Discrimination by SZL49 between contractions evoked by noradrenaline in longitudinal and circular muscle of human vas deferens.

Authors:  Nnaemeka I B Amobi; John Guillebaud; A V Kaisary; Eileen Turner; I Christopher H Smith
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

4.  Alpha-adrenoceptor mediated responses of the cauda epididymis of the guinea-pig.

Authors:  J M Haynes; S J Hill
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

5.  Identification of the alpha1L-adrenoceptor in rat cerebral cortex and possible relationship between alpha1L- and alpha1A-adrenoceptors.

Authors:  S Morishima; F Suzuki; H Yoshiki; A S Md Anisuzzaman; Z S Sathi; T Tanaka; I Muramatsu
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

Review 6.  Subtypes of functional alpha1-adrenoceptor.

Authors:  James R Docherty
Journal:  Cell Mol Life Sci       Date:  2009-10-28       Impact factor: 9.261

7.  Identification of alpha 1L-adrenoceptor in mice and its abolition by alpha 1A-adrenoceptor gene knockout.

Authors:  I Muramatsu; S Morishima; F Suzuki; H Yoshiki; A S M Anisuzzaman; T Tanaka; M C Rodrigo; B E Myagmar; P C Simpson
Journal:  Br J Pharmacol       Date:  2008-09-22       Impact factor: 8.739

8.  Different subtypes of alpha 1A-adrenoceptor mediating contraction of rat epididymal vas deferens, rat hepatic portal vein and human prostate distinguished by the antagonist RS 17053.

Authors:  I Marshall; R P Burt; G M Green; M B Hussain; C R Chapple
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

Review 9.  Classification of alpha 1-adrenoceptor subtypes.

Authors:  M C Michel; B Kenny; D A Schwinn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-07       Impact factor: 3.000

10.  Relation between alpha 1-adrenoceptor subtypes and noradrenaline-induced contraction in rat portal vein smooth muscle.

Authors:  I Sayet; G Neuilly; L Rakotoarisoa; C Mironneau; J Mironneau
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.